Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Sosei Group announces Phase III trials update on NVA237 and QVA149

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announces that the Phase III trials with NVA237, which commenced in June 2009, are proceeding to plan. Initiation of Phase III studies with QVA149 is now expected to occur during 2010.

22 Oct 2009

Findings may yield new treatments for COPD

A genetic mutation found in four children born with multiple abnormalities may provide insight into potential treatments for newborn lung distress and chronic obstructive pulmonary disease (COPD).

19 Oct 2009

Invacare Corporation's initiative to raise awareness of Chronic Obstructive Pulmonary Disease

Invacare Corporation is sponsoring a bicycle expedition to raise awareness of Chronic Obstructive Pulmonary Disease (COPD) and inspire oxygen users to live active lives. The cyclist, Mark Junge, will be using the Invacare® XPO2™ Portable Oxygen Concentrator on his 816-mile trip. He will begin in New York City’s Times Square on October 15, 2009, and complete the trek in Charleston, South Carolina, on November 2, 2009.

14 Oct 2009

University of Nottingham pioneers new type of MRI scan

People with chronic lung disease and asthma could soon be offered better treatment thanks to a new type of Magnetic Resonance Imaging (MRI) scan being pioneered at The University of Nottingham.

13 Oct 2009

Patient outcomes better in highly rated hospitals than others

The largest annual study of patient outcomes at each of the nation's 5,000 nonfederal hospitals found a wide gap in quality between the nation's best hospitals and all others. According to the study, issued today by HealthGrades, the leading independent healthcare ratings organization, patients at highly rated hospitals have a 52 percent lower chance of dying compared with the U.S. hospital average, a quality chasm that has persisted for the last decade even as mortality rates, in general, have declined.

13 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

COPD Management Program for South Region TRICARE beneficiaries

Humana Military Healthcare Services, a wholly owned subsidiary of Humana Inc., announced today an additional benefit available for South Region TRICARE beneficiaries. The Chronic Obstructive Pulmonary Disease (COPD) Management Program offers telephonic education and coaching by dedicated registered nurses.

12 Oct 2009

Bio-Matrix Scientific Group provides updates on COPD research

Bio-Matrix Scientific Group, Inc. provided a progress report on the Company’s previously announced new opportunities. The Company has been moving forward in the areas of stem cell research for treatment of Chronic Obstructive Pulmonary Disease (COPD), Tumor Banking and Cancer Treatment.

12 Oct 2009

Multi-center Lung Genomics Research Consortium to study fatal lung diseases

Researchers at five research centers have been awarded an $11 million, two-year grant from the National Heart Lung and Blood Institute as part of the NIH Recovery Act that will allow a team of national scientists to delve deeply into the biology of two fatal lung diseases for which there are few therapeutic options.

8 Oct 2009

Triple therapy may benefit patients with chronic obstructive pulmonary disease

Patients with moderate to severe chronic obstructive pulmonary disease (COPD) can benefit from triple therapy that includes a long-acting β-agonist (LABA), an inhaled corticosteroid (ICS) and an anti-muscarinic agent, according to researchers in Germany.

8 Oct 2009

NHLBI awards $11 million to research on the biology of two fatal lung diseases

Researchers at National Jewish Health and four other research centers have been awarded an $11 million, two-year grant from the National Heart Lung and Blood Institute as part of the NIH Recovery Act that will allow a team of national scientists to delve deeply into the biology of two fatal lung diseases for which there are few therapeutic options.

8 Oct 2009

Ventilation mask leakage may contaminate hospital setting

New research shows that certain noninvasive positive pressure ventilation (NPPV) masks may leak exhaled air up to a distance of 1 m from patients receiving treatments.

6 Oct 2009

Respiragene test for lung cancer motivates smokers to quit smoking

Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.

1 Oct 2009

Identification of nitric oxide using lasers and sensors

Nitric oxide, a gas well known to scientists for its myriad functions, has proven challenging to measure accurately outside the laboratory. A team of Princeton and Rice University researchers has demonstrated a new method of identifying the gas using lasers and sensors that are inexpensive, compact and highly sensitive. Such a portable device, suitable for large-scale deployment, could be of great value to atmospheric science, pollution control, biology and medicine.

21 Sep 2009

Strategies for reducing tobacco use and health care costs in the U.S.

The Communities Putting Prevention to Work initiative announced today by the U.S. Department of Health and Human Services, which includes support for strategies to reduce tobacco use, is a smart investment in the nation's health that will save lives, prevent disease and help reduce health care costs.

18 Sep 2009

Genetically removing the osteopontin protein prevents lung diseases

In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).

16 Sep 2009

Novartis presents Phase II results of the QVA149 bronchodilator for the treatment of COPD

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announce that Novartis have presented the results of their two Phase II studies evaluating the efficacy, safety and tolerability of QVA149 at the annual congress of the European Respiratory Society (ERS) in Vienna.

16 Sep 2009

Biotie Therapies commences clinical trial with its phosphodiesterase 4 inhibitor ELB353

Biotie has started a clinical trial with its phosphodiesterase 4 (PDE4) inhibitor ELB353, having received the prerequisite regulatory and ethical clearances for the clinical trial application.

14 Sep 2009

Altair announces positive Phase I results for AIR645 in treating asthma

Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, today announced positive results from a phase I multiple dose safety and pharmacokinetic study of its lead product, once-weekly inhaled AIR645 in healthy adults and mild asthmatics.

14 Sep 2009

Chronic pediatric cough linked to reflux and allergies

New research shows that chronic cough in children is most often caused by gastroesophageal reflux and allergies. Researchers from Tulane University in New Orleans, LA, evaluated 40 patients aged 5 to 12 years with chronic cough (> 8 weeks in duration) with no obvious cause. Each patient underwent extensive multispecialty testing. Results showed that reflux was the single most commonly associated factor of chronic cough by itself (27.5 percent), followed by allergy (22.5 percent).

8 Sep 2009